Trial Profile

An Open-Label Phase I Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of YY001 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YY 001 Shanghai Yuyao Biotech (Primary)
Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Shanghai Yuyao Biotech

Most Recent Events

03 Jan 2025 Status changed from active, no longer recruiting to completed.
04 Jun 2024 Results assessing safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumorspresented at the 60th Annual Meeting of the American Society of Clinical Oncology
05 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com